Trapidil

Trapidil
Clinical data
Trade names	Rocornal, Avantrin, Travisco
AHFS/Drugs.com	International Drug Names
Routes of; administration	By mouth
ATC code	C01DX11 (WHO) ;
Legal status
Legal status	US: Not approved; In general: ℞ (Prescription only);
Identifiers
	IUPAC name N,N-Diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;
CAS Number	15421-84-8 N;
PubChem CID	5531;
ChemSpider	5330 N;
UNII	EYG5Y6355E;
CompTox Dashboard (EPA)	DTXSID0045416 ;
ECHA InfoCard	100.035.834
Chemical and physical data
Formula	C10H15N5
Molar mass	205.265 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)c1cc(nc2n1ncn2)C;
	InChI InChI=1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3 N; Key:GSNOZLZNQMLSKJ-UHFFFAOYSA-N N;
	NY (what is this?) (verify)

Trapidil is used in the treatment of chronic stable angina pectoris. It is currently marketed in Japan under the brand name Rocornal.¹

An analog was assigned the codename AR 12-456.²

Pharmacology

Based on cell free in vitro activity assays, trapidil at therapeutic concentrations causes selective phosphorylation of cellular proteins through positive modulation of regulatory subunit RII(α/β) containing protein kinase A (PKA).³⁴ At higher, non-physiologically relevant concentrations, which are generally not achieved after administration of therapeutic doses, non-selective inhibition of phosphodiesterases occurs.⁴ Further, the previous documented activities as an antagonist of platelet-derived growth factor⁵ are abolished when a PKA inhibitor is administered, suggesting that these noted activities are PKA mediated.⁴ At these higher concentrations,⁶ additional effects have been noted including vasodilation and inhibition of platelet aggregation⁷⁸

References

"ロコルナール錠100mg | 持田製薬株式会社". med.mochida.co.jp. Retrieved 2025-10-09.
Hering S, Bodewei R, Schubert B, Krause EG, Wollenberger A (1985). "Trapidil and other 5-triazolo-(1, 5-alpha)-pyrimidine derivatives as calcium channel blockers in 108CC5 cells". Biomedica Biochimica Acta. 44 (5): K37–K41. PMID 2415119.
Sichelschmidt OJ, Hahnefeld C, Hohlfeld T, Herberg FW, Schrör K (June 2003). "Trapidil protects ischemic hearts from reperfusion injury by stimulating PKAII activity". Cardiovascular Research. 58 (3): 602–610. doi:10.1016/S0008-6363(03)00261-X. PMID 12798433.
Bönisch D, Weber AA, Wittpoth M, Osinski M, Schrör K (August 1998). "Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase A". Molecular Pharmacology. 54 (2): 241–248. doi:10.1124/mol.54.2.241. PMID 9687564.
Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, et al. (December 1994). "Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica". Circulation. 90 (6): 2710–2715. doi:10.1161/01.cir.90.6.2710. PMID 7994812.
"Trapidil Professional Information (Summary of Product Characteristics/SPC)". Federal Institute for Drugs and Medical Devices (German). January 2019. Retrieved October 9, 2025.
Büyükafşar K, Yazar A, Düşmez D, Oztürk H, Polat G, Levent A (October 2001). "Effect of trapidil, an antiplatelet and vasodilator agent on gentamicin-induced nephrotoxicity in rats". Pharmacological Research. 44 (4): 321–328. doi:10.1006/phrs.2001.0864. PMID 11592868.
Liu M, Sun Q, Wang Q, Wang X, Lin P, Yang M, et al. (March–April 2014). "Effect of trapidil in myocardial ischemia-reperfusion injury in rabbit". Indian Journal of Pharmacology. 46 (2): 207–210. doi:10.4103/0253-7613.129320. PMC 3987192. PMID 24741195.

[1] "ロコルナール錠100mg | 持田製薬株式会社". med.mochida.co.jp. Retrieved 2025-10-09.

[2] Hering S, Bodewei R, Schubert B, Krause EG, Wollenberger A (1985). "Trapidil and other 5-triazolo-(1, 5-alpha)-pyrimidine derivatives as calcium channel blockers in 108CC5 cells". Biomedica Biochimica Acta. 44 (5): K37–K41. PMID 2415119.

[3] Sichelschmidt OJ, Hahnefeld C, Hohlfeld T, Herberg FW, Schrör K (June 2003). "Trapidil protects ischemic hearts from reperfusion injury by stimulating PKAII activity". Cardiovascular Research. 58 (3): 602–610. doi:10.1016/S0008-6363(03)00261-X. PMID 12798433.

[Bonisch_1998-4] Bönisch D, Weber AA, Wittpoth M, Osinski M, Schrör K (August 1998). "Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase A". Molecular Pharmacology. 54 (2): 241–248. doi:10.1124/mol.54.2.241. PMID 9687564.

[5] Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, et al. (December 1994). "Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica". Circulation. 90 (6): 2710–2715. doi:10.1161/01.cir.90.6.2710. PMID 7994812.

[6] "Trapidil Professional Information (Summary of Product Characteristics/SPC)". Federal Institute for Drugs and Medical Devices (German). January 2019. Retrieved October 9, 2025.

[7] Büyükafşar K, Yazar A, Düşmez D, Oztürk H, Polat G, Levent A (October 2001). "Effect of trapidil, an antiplatelet and vasodilator agent on gentamicin-induced nephrotoxicity in rats". Pharmacological Research. 44 (4): 321–328. doi:10.1006/phrs.2001.0864. PMID 11592868.

[8] Liu M, Sun Q, Wang Q, Wang X, Lin P, Yang M, et al. (March–April 2014). "Effect of trapidil in myocardial ischemia-reperfusion injury in rabbit". Indian Journal of Pharmacology. 46 (2): 207–210. doi:10.4103/0253-7613.129320. PMC 3987192. PMID 24741195.

1

2

3

4

5

6

7

8